Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. / Lambertini, Matteo; Kroman, Niels; Ameye, Lieveke; Cordoba, Octavi; Pinto, Alvaro; Benedetti, Giovanni; Jensen, Maj-Britt; Gelber, Shari; Del Grande, Maria; Ignatiadis, Michail; de Azambuja, Evandro; Paesmans, Marianne; Peccatori, Fedro A; Azim, Hatem A.
I: Journal of the National Cancer Institute, Bind 110, Nr. 4, 2018, s. 426-429.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status
AU - Lambertini, Matteo
AU - Kroman, Niels
AU - Ameye, Lieveke
AU - Cordoba, Octavi
AU - Pinto, Alvaro
AU - Benedetti, Giovanni
AU - Jensen, Maj-Britt
AU - Gelber, Shari
AU - Del Grande, Maria
AU - Ignatiadis, Michail
AU - de Azambuja, Evandro
AU - Paesmans, Marianne
AU - Peccatori, Fedro A
AU - Azim, Hatem A
PY - 2018
Y1 - 2018
N2 - Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.
AB - Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.
U2 - 10.1093/jnci/djx206
DO - 10.1093/jnci/djx206
M3 - Journal article
C2 - 29087485
VL - 110
SP - 426
EP - 429
JO - National Cancer Institute. Journal (Print)
JF - National Cancer Institute. Journal (Print)
SN - 0027-8874
IS - 4
ER -
ID: 212685583